ACTU (Actuate Therapeutics, Inc.) מכפיל P/E עתידי

Actuate Therapeutics, Inc. (ACTU) relies on outsourcing production and testing, maintaining agility through external contractors without incurring massive costs. The business focuses on oncology therapies, developing innovative methods for patient care. The current P/E ratio is 0.00. Meanwhile, the company is spending reserves on clinical development without generating revenue, which is confirmed by this price chart reflecting financial strain.
פילוחי נתונים אנליטיים מרוכזים עבור Actuate Therapeutics, Inc. (ACTU)

Forward P/E is calculated as the ratio of current market capitalization to projected net income. This metric determines the extent to which investors are overpaying for future earnings, helping to identify overheated assets. For Actuate Therapeutics, Inc. (ACTU), high R&D expenditures and the anticipation of Phase II trial results render this calculation speculative. The market has already priced development risks into the quotes. Analyze the company's projected price-to-earnings ratio to assess fundamental risks.